DE60003289D1 - Kombinationstherapie für lymphoproliferative krankheiten - Google Patents

Kombinationstherapie für lymphoproliferative krankheiten

Info

Publication number
DE60003289D1
DE60003289D1 DE60003289T DE60003289T DE60003289D1 DE 60003289 D1 DE60003289 D1 DE 60003289D1 DE 60003289 T DE60003289 T DE 60003289T DE 60003289 T DE60003289 T DE 60003289T DE 60003289 D1 DE60003289 D1 DE 60003289D1
Authority
DE
Germany
Prior art keywords
combination therapy
lymphoproliferative diseases
host
diseases
lymphoproliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60003289T
Other languages
English (en)
Other versions
DE60003289T2 (de
Inventor
C Byrd
R Grever
W Flinn
K Waselenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma PLC
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Application granted granted Critical
Publication of DE60003289D1 publication Critical patent/DE60003289D1/de
Publication of DE60003289T2 publication Critical patent/DE60003289T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60003289T 1999-02-24 2000-01-19 Kombinationstherapie für lymphoproliferative krankheiten Expired - Lifetime DE60003289T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US256666 1999-02-24
US09/256,666 US6316435B2 (en) 1999-02-24 1999-02-24 Combination therapy for lymphoproliferative diseases
PCT/US2000/001180 WO2000050082A1 (en) 1999-02-24 2000-01-19 Combination therapy for lymphoproliferative diseases

Publications (2)

Publication Number Publication Date
DE60003289D1 true DE60003289D1 (de) 2003-07-17
DE60003289T2 DE60003289T2 (de) 2004-04-29

Family

ID=22973107

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60003289T Expired - Lifetime DE60003289T2 (de) 1999-02-24 2000-01-19 Kombinationstherapie für lymphoproliferative krankheiten

Country Status (6)

Country Link
US (1) US6316435B2 (de)
EP (1) EP1156828B1 (de)
AT (1) ATE242642T1 (de)
AU (1) AU2967700A (de)
DE (1) DE60003289T2 (de)
WO (1) WO2000050082A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080554B2 (en) 2001-12-12 2011-12-20 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US6841565B1 (en) * 2002-03-29 2005-01-11 The Ohio State University Treatment of patients with chronic lymphocytic leukemia
US20050207998A1 (en) * 2003-07-21 2005-09-22 Yaoping Lu Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
AU2006210746B2 (en) * 2005-02-03 2012-04-26 Topotarget Uk Limited Combination therapies using HDAC inhibitors
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP2425830A1 (de) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistische Arzneimittelkombination zur Behandlung von Krebs
WO2012064671A1 (en) 2010-11-08 2012-05-18 The Ohio State University Research Foundation Compositions and methods for increasing drug efficacy in cancer
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
SG11201401260QA (en) 2011-11-23 2014-07-30 Novartis Ag Pharmaceutical formulations
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease

Also Published As

Publication number Publication date
WO2000050082A1 (en) 2000-08-31
ATE242642T1 (de) 2003-06-15
EP1156828B1 (de) 2003-06-11
US6316435B2 (en) 2001-11-13
DE60003289T2 (de) 2004-04-29
EP1156828A1 (de) 2001-11-28
AU2967700A (en) 2000-09-14
US20010006974A1 (en) 2001-07-05

Similar Documents

Publication Publication Date Title
AU2713500A (en) Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
PT1214936E (pt) Utilizacao de derivados de tiazolidina ou pirrolidina de aminoacidos como agentes anti-hiperglicemicos
EE04528B1 (et) Teraapias kasutatavad spirofuropridiinide aralklamiinid
IL223875A (en) Use of chondroitinase in the preparation of a drug for use in a method of promoting neural flexibility
AU5624699A (en) Use of 5ht-6 antagonists
DE69532942D1 (de) Unabhängige, angetriebene, chirurgische Vorrichtung
ATE264863T1 (de) 28-epirapaloge
ATE242642T1 (de) Kombinationstherapie für lymphoproliferative krankheiten
BR9911781B1 (pt) iluminador para terapia fotodinámica.
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
BR9814923A (pt) Método para tratamento de doença de alzheimer
HK1080284A1 (en) Pharmaceutical composition for treatment of rhinitis
TR200000695T2 (tr) Cildin durumunu iyileştirmek için bir yöntem.
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
TR199900951T2 (xx) G���s kanserinin engellenmesi i�in y�ntemler.
ATE306977T1 (de) Schaukel für behinderte
BR9907746A (pt) ácidos 2,3,4,5-tetraidro-1h[1,4]-benzodiazepina-3-hidroxâmic os como inibidores de matriz de metaloproteinase
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
DE50016051D1 (de) Oberflächenbehandlungsmittel für dentales hartgewebe
IL134479A0 (en) Process for producing a transdermal therapeutic system with protection against oral use
TR199901546A2 (xx) Pirolidinil hidroksamik asid bile�imleri i�in y�ntem.
MD1473F2 (en) Antiherpetic remedy
ATE222103T1 (de) Inklusionskomplexe in waessriger loesung
CO5170459A1 (es) Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: SCHIEBER FARAGO, 80538 MUENCHEN

8327 Change in the person/name/address of the patent owner

Owner name: MAYNE PHARMA PLC., LEAMINGTON SPA, GB